Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Urology

Surgery

Show all topics

DOI

10.1016/s1470-2045(21)00147-9